AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10455090 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta SPP (difference between exercise and rest SPP)
Number of subjects: 40
Study 8556905 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-second delay
Number of subjects: 0
Study 8556905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute delay
Number of subjects: 0
Study 8556905 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing reminders of the model and its relevance
Number of subjects: 0
Study 8556905 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience in using the model
Number of subjects: 0
Study 2378793 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (2.5 mg kg‐1 in 10 min, followed by 5 mg kg‐1 h‐1 for 200 min)
Number of subjects: 6
Study 2378793 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 2378793 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 6
Study 141634 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 50 mg daily
Number of subjects: 30
Study 141634 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 100 mg daily
Number of subjects: 30
Study 141634 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg daily
Number of subjects: 30
Study 31735553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus gB-MF59 vaccine
Number of subjects: 0
Study 31735553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30095776 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mL buffered 1% lidocaine paracervical block
Number of subjects: 64
Study 30095776 — intervention group
Group type: COMPARATOR
Intervention: No block (placebo)
Number of subjects: 64
Study 27553916 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe bladder dysfunction (n=49)
Number of subjects: 92
Study 27553916 — intervention group
Group type: COMPARATOR
Intervention: None-mild bladder dysfunction (n=43)
Number of subjects: 92
Study 25293475 — intervention group
Group type: EXPERIMENTAL
Intervention: GRVprototype
Number of subjects: 37
Study 25293475 — intervention group
Group type: COMPARATOR
Intervention: IBP
Number of subjects: 37
Study 25293475 — intervention group
Group type: EXPERIMENTAL
Intervention: IGP
Number of subjects: 37
Study 23206440 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Mai-San (SMS)
Number of subjects: 100
Study 23206440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18722681 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 27
Study 18722681 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 27
Study 18722681 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 17548525 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude-expressive goal made salient
Number of subjects: 0
Study 17548525 — intervention group
Group type: EXPERIMENTAL
Intervention: High time pressure with attitude-expressive goal
Number of subjects: 0
Study 17548525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias at exposure
Number of subjects: 0
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization during hospitalization
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins administration
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis of angina
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis of myocardial infarction
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis of other conditions
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 28 days
Number of subjects: 1877
Study 15766446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 6 months
Number of subjects: 1877
Study 14625173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 64
Study 14625173 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 64
Study 11114686 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial milk with added long-chain polyunsaturated fatty acids (LCPs)
Number of subjects: 140
Study 11114686 — intervention group
Group type: COMPARATOR
Intervention: Standard formula milk
Number of subjects: 140
Study 9026373 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg Tianeptine (TIA)
Number of subjects: 16
Study 9026373 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg Tianeptine (TIA)
Number of subjects: 16
Study 9026373 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Fluvoxamine (FLU)
Number of subjects: 16
Study 9026373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1791622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynical hostility (measured by Cook and Medley Hostility Scale) during discussion task with incentive to exert control
Number of subjects: 0
Study 1791622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynical hostility (measured by Cook and Medley Hostility Scale) during discussion task without incentive to exert control
Number of subjects: 0
Study 1791622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynical hostility (measured by Cook and Medley Hostility Scale)
Number of subjects: 0
Study 6136793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice and cholestyramine, nicotinic acid, or clofibrate depending on lipoprotein phenotype
Number of subjects: 24
Study 6136793 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 24
Study 30922594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 60
Study 30922594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29030268 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin plus standard of care
Number of subjects: 0
Study 29030268 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 27797984 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blind HT arm
Number of subjects: 0
Study 27797984 — intervention group
Group type: COMPARATOR
Intervention: Blind HT arm
Number of subjects: 0
Study 27797984 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blind HT arm (higher education)
Number of subjects: 0
Study 27797984 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blind HT arm (never-smokers)
Number of subjects: 0
Study 27797984 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blind HT arm (subjective symptoms)
Number of subjects: 0
Study 24818210 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen sponge covering fresh sockets (group 1)
Number of subjects: 23
Study 24818210 — intervention group
Group type: COMPARATOR
Intervention: Corticocancellous porcine bone graft (group 2)
Number of subjects: 23
Study 21569111 — intervention group
Group type: EXPERIMENTAL
Intervention: 1550-nm non-ablative fractional photothermolysis (NFP) treatment; 4 sessions at 3-week intervals, energy: 15 mJ/MTZ, total density: 1048 MTZs/cm², density per pass: 131 MTZs/cm², total coverage: 20%
Number of subjects: 51
Study 21569111 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum sunscreen alone
Number of subjects: 51
Study 21569111 — intervention group
Group type: EXPERIMENTAL
Intervention: 1550-nm non-ablative fractional photothermolysis (NFP) treatment
Number of subjects: 51
Study 19944418 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus tamoxifen
Number of subjects: 150
Study 19944418 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling
Number of subjects: 150
Study 16876301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic agonist (piribedil 50 mg/day)
Number of subjects: 40
Study 16876301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15765306 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-drug regimen: zidovudine/lamivudine/abacavir/nevirapine
Number of subjects: 28
Study 12394652 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI‐1 activity (chromogenic substrate kinetic assay)
Number of subjects: 170
Study 12394652 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI‐1 protein (enzyme‐linked immunosorbent assay)
Number of subjects: 170
Study 9573500 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pulmonary infections (all etiologies mixed)
Number of subjects: 181
Study 9573500 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous opportunistic infections (all etiologies mixed)
Number of subjects: 181
Study 9573500 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since the diagnosis of acquired immunodeficiency syndrome more than 12 months
Number of subjects: 181
Study 7523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sussex dataset
Number of subjects: 500
Study 7523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Leiden dataset
Number of subjects: 500
Study 7523908 — intervention group
Group type: COMPARATOR
Intervention: Vermont dataset
Number of subjects: 500
Study 7523908 — intervention group
Group type: COMPARATOR
Intervention: Paris dataset
Number of subjects: 500
Study 2975553 — intervention group
Group type: COMPARATOR
Intervention: Twice daily insulin regimen
Number of subjects: 10
Study 2975553 — intervention group
Group type: COMPARATOR
Intervention: Premixed 50:50 regimen
Number of subjects: 10
Study 2975553 — intervention group
Group type: COMPARATOR
Intervention: Premixed 30:70 regimen
Number of subjects: 10
Study 2975553 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal and prandial regimen
Number of subjects: 10
Study 31498127 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 25mg
Number of subjects: 1614
Study 31498127 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 50mg
Number of subjects: 1614
Study 31498127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1614
Study 31498127 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label Opicapone
Number of subjects: 1614
Study 31498127 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (Phase-3 clinical program)
Number of subjects: 1614
Study 29496007 — intervention group
Group type: COMPARATOR
Intervention: Thermo-neutral beverage (TN)
Number of subjects: 7
Study 29496007 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling with ice slurry beverage and iced towels (PRE)
Number of subjects: 7
Study 29496007 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling with ice slurry beverage and iced towels plus ice slurry ingestion during cycling (PRE + MID)
Number of subjects: 7
Study 26963434 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) before ischemic-reperfusion (I-R) injury
Number of subjects: 20
Study 26963434 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) after ischemic-reperfusion (I-R) injury
Number of subjects: 20
Study 26963434 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) with remote conditioning (preischemic)
Number of subjects: 20
Study 26963434 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) with remote conditioning (postischemic)
Number of subjects: 20
Study 25085598 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation Maps™ (CM) education
Number of subjects: 310
Study 25085598 — intervention group
Group type: COMPARATOR
Intervention: Regular care (RC)
Number of subjects: 310
Study 22414635 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin administration (0.8 ng/kg)
Number of subjects: 9
Study 22414635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20807453 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour interactive EBM workshop
Number of subjects: 48
Study 20807453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 48
Study 20807453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (workshop and control)
Number of subjects: 48
Study 17645512 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 90
Study 17645512 — intervention group
Group type: EXPERIMENTAL
Intervention: gutta‐percha/AH Plus
Number of subjects: 90
Study 17645512 — intervention group
Group type: COMPARATOR
Intervention: positive controls
Number of subjects: 90
Study 17645512 — intervention group
Group type: COMPARATOR
Intervention: negative controls
Number of subjects: 90
Study 16305007 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental chewable toothbrush
Number of subjects: 14
Study 16305007 — intervention group
Group type: COMPARATOR
Intervention: Control manual toothbrush
Number of subjects: 14
Study 12243435 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) during CPB
Number of subjects: 18
Study 12243435 — intervention group
Group type: COMPARATOR
Intervention: Control group (without MUF)
Number of subjects: 18
Study 9836029 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 mg loading dose, 1 mg in 4 ml bupivacaine 0.125%)
Number of subjects: 40
Study 9836029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 micrograms loading dose, 20 micrograms in 4 ml bupivacaine 0.125%)
Number of subjects: 40
Study 7984747 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait Anxiety scale of Spielberger's State-Trait Anxiety Inventory for Children
Number of subjects: 157
Study 3051044 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 'Franol' tablets
Number of subjects: 30
Study 3051044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 'Franol' tablet
Number of subjects: 30
Study 3051044 — intervention group
Group type: COMPARATOR
Intervention: 2 placebo tablets
Number of subjects: 30
Study 30037276 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 42
Study 30037276 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 42
Study 6111457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol on weight maintenance diet
Number of subjects: 0
Study 6111457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol during semistarvation
Number of subjects: 0
Study 6111457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol on both diets
Number of subjects: 0
Study 30883951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous anaesthesia (IOA) delivered by QuickSleeper™
Number of subjects: 158
Study 30883951 — intervention group
Group type: COMPARATOR
Intervention: Conventional infiltration anaesthesia (CIA)
Number of subjects: 158
Study 28467015 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 10 J/cm2 (B10)
Number of subjects: 42
Study 28467015 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 30 J/cm2 (B30)
Number of subjects: 42
Study 28467015 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 70 J/cm2 (B70)
Number of subjects: 42
Study 28467015 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 90 J/cm2 (B90)
Number of subjects: 42
Study 28467015 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation at 110 J/cm2 (B110)
Number of subjects: 42
Study 28467015 — intervention group
Group type: COMPARATOR
Intervention: Control group (B0, not subjected to laser irradiation)
Number of subjects: 42
Study 26525410 — intervention group
Group type: EXPERIMENTAL
Intervention: WATI enhanced with proactive, pushed tailored email motivational messaging (messaging)
Number of subjects: 4789
Study 26525410 — intervention group
Group type: EXPERIMENTAL
Intervention: WATI with messaging further enhanced with personal secure messaging with a tobacco treatment specialist and an online support group (personalized)
Number of subjects: 4789
Study 26525410 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art tailored WATI control
Number of subjects: 4789
Study 26525410 — intervention group
Group type: EXPERIMENTAL
Intervention: ePortal implementation
Number of subjects: 4789
Study 24187859 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Huadananshen mistura (10 mL/day)
Number of subjects: 244
Study 24187859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Huadananshen mistura (20 mL/day)
Number of subjects: 244
Study 24187859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 24187859 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 244
Study 21192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial distress measured with the Symptom Checklist-90-Revised (SCL-90-R)
Number of subjects: 293
Study 21192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial distress measured with the SCL-90-R
Number of subjects: 293
Study 21192290 — intervention group
Group type: EXPERIMENTAL
Intervention: SCL-90 and pain intensity as predictors of RMDQ
Number of subjects: 293
Study 21192290 — intervention group
Group type: EXPERIMENTAL
Intervention: All baseline characteristics analyzed in relation to RMDQ
Number of subjects: 293
Study 19647940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-annular PIRFT
Number of subjects: 20
Study 19647940 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 17283313 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE-epsilon4 carriers with long duration of epilepsy
Number of subjects: 87
Study 17283313 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE-epsilon4 carriers
Number of subjects: 87
Study 17283313 — intervention group
Group type: COMPARATOR
Intervention: non-epsilon4 carriers
Number of subjects: 87
Study 15531677 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-fortified salt (TFS) with 30 mug I, 2 mg Fe, and 60 mug vitamin A/g salt
Number of subjects: 157
Study 15531677 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 157
Study 11514766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-invasive static nail (experimental device with a locked intramedullary nail and two nonparallel seven-millimeter cervicocephalic screws)
Number of subjects: 60
Study 11514766 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (sliding screw plate)
Number of subjects: 60
Study 9779766 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV (Group 1)
Number of subjects: 115
Study 9779766 — intervention group
Group type: COMPARATOR
Intervention: DT-IPV (Group 2)
Number of subjects: 115
Study 7930242 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated heparin therapy (n = 118)
Number of subjects: 238
Study 7930242 — intervention group
Group type: COMPARATOR
Intervention: 24-hour heparin therapy (n = 120)
Number of subjects: 238
Study 3066803 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental interventions based on self‐efficacy and family stress theory during hospitalization and for 3 months thereafter
Number of subjects: 67
Study 3066803 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 31609869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair yoga
Number of subjects: 0
Study 31609869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-based exercise
Number of subjects: 0
Study 31609869 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 29211741 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture sessions (up to twelve sessions)
Number of subjects: 0
Study 29211741 — intervention group
Group type: COMPARATOR
Intervention: Alexander Technique lessons (up to twenty lessons)
Number of subjects: 0
Study 26293196 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention preparation (reading a training manual and demonstration on a teddy bear)
Number of subjects: 60
Study 26293196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preintervention preparation)
Number of subjects: 60
Study 24188638 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based distribution program by SWAP
Number of subjects: 0
Study 22110268 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation with Peg-IFN-α 2b plus ribavirin
Number of subjects: 69
Study 19396424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-guided pump management
Number of subjects: 62
Study 19396424 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard insulin pump regimen)
Number of subjects: 62
Study 19396424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-guided pump management (within intervention group)
Number of subjects: 62
Study 16793944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol (or-EE) 100 microg/day
Number of subjects: 50
Study 16793944 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 250 mg twice a week
Number of subjects: 50
Study 16793944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA) 100 mg/day
Number of subjects: 50
Study 16793944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (td-E) 100 microg twice a week
Number of subjects: 50
Study 16793944 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (both routes)
Number of subjects: 50
Study 14666945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU per kg vitamin E plus placebo)
Number of subjects: 7
Study 14666945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g per day vitamin C plus placebo)
Number of subjects: 7
Study 14666945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo plus placebo)
Number of subjects: 7